INTRODUCTION
The serine proteinase single-chain urokinase-type plasminogen activator (scu-PA), also called pro-urokinase, can, when converted into two-chain urokinase-type plasminogen activator (tcu-PA), activate plasminogen to plasmin. The activator probably has an important role in fibrinolysis and in the maintenance of the haemostatic balance [for reviews, see Lijnen et al. (1987a) , Gurewich (1988) and de Munk and Rijken (1990) ]. In contrast with plasmin and kallikrein, which cleave scu-PA between Lys-158 and Ile-159, resulting in an active two-chain molecule, thrombin cleaves scu-PA between Arg-1 56 and Phe-1 57, resulting in an-inactive two-chain molecule (Bernik and Oller, 1977; Ichinose et al., 1986; Gurewich and Pannell, 1987) . Thrombininactivated scu-PA is very poorly activated by plasmin (Lijnen et al., 1987b) .
Thrombomodulin (TM), an endothelial-cell-membrane proteoglycan, binds thrombin with high affinity in a 1: 1 complex. The protein stimulates the anticoagulant properties of thrombin by accelerati2g the activation of protein C and inhibits the procoagulant properties of thrombin [for reviews, see Freyssinet and Cazenave (1988) , N. L. Esmon (1987) , C. T. Esmon (1989) and Dittman and Majerus (1990) ]. Besides these anticoagulant effects, TM may also have an antifibrinolytic effect by accelerating the inactivation of scu-PA by thrombin (De Munk et al., 1991; Molinari et al., 1992) .
TM contains many N-and 0-linked glycans (Bourin et Koyama et al., 1991a; Parkinson et al., 1992) . One 0-linked chondroitin sulphate-like glycosaminoglycan (CSGAG) in TM constitutes a secondary binding site for thrombin (Bourin et al., 1988; Preissner et al., 1990) in addition to the primary binding site on the epidermal-growth-factor domains 5 and 6 of TM (Kurosawa et al., 1988; Hayashi et al., 1990) . This CSGAG potentiates inhibition of thrombin's activity towards fibrinogen and other bulky substrates (Bourin et al., 1988; Preissner et al., 1990; Parkinson et al., 1990; Nawa et al., 1990) , and is essential for the acceleration of thrombin inhibition by antithrombin III (Preissner et al., 1990; Bourin et al., 1988; Nawa et al., 1990; Koyama et at., 1991b) . The CSGAG also significantly enhances protein C activation by the thrombin-TM complex at physiological Ca2+ concentrations (Parkinson et al., 1990 (Parkinson et al., , 1992 . At low Ca2" concentrations, the CSGAG has, however, a less critical function in the activation of protein C (Preissner et al., 1990; Parkinson et al., 1990 Parkinson et al., , 1992 . Various molecular models have recently been designed to illustrate the role of the CSGAG in the interaction between TM, thrombin and different substrates Preissner et al., 1990; Koyama et al., 1991b rec-TM lacking the 0-linked CSGAG (Parkinson et al., 1990 (Parkinson et al., , 1992 . In addition we modified TM chemically and enzymically.
MATERIALS AND METHODS Materials
Human scu-PA and low-Mr scu-PA, lacking the N-terminal part of the molecule (the epidermal-growth-factor domain and kringle domain), were isolated from embryonic kidney cell cultures (Badylak et al., 1988) and donated by Dr. J. Henkin (Abbott Laboratories, Abbott Park, IL, U.S.A.). Rabbit lung TM (Mr 74000; Esmon et al., 1982) was purchased from American Diagnostica (Greenwich, CT, U.S.A.). Soluble human highand low-Mr recombinant thrombomodulins (rec-TM) with Mr 105 000 and Mr 75 000 respectively were purified from conditioned medium of stable 293 cell transformants, as recently described (Parkinson et al., 1990 (Parkinson et al., , 1992 . Hirudin was from Pentapharm (Basel, Switzerland). Human plasmin and the chromogenic substrate Glp-Gly-Arg p-nitroanilide (S-2444) were from Kabi AB (Stockholm, Sweden). Aprotinin was from Bayer AG (Leverkusen-Bayerwerk, Germany). Human thrombin (T6759), BSA (A7030), chondroitinase ABC (C2905), pepstatin (P4265), leupeptin (L2884), chondroitin sulphate A (C8529) were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). A specific activity of 3.3 N.I.H. units/,ug for thrombin (as indicated by the manufacturer) and Mr 37000 were used for the calculation of concentrations.
Assay of scu-PA The amount of scu-PA was determined by activating scu-PA (3.7 nM), in 20 mM Tris/HCl (pH 7.5)/100 mM NaCl/3 mM CaCl2/0.1% BSA/0. 1% Tween-80/hirudin (see below), with plasmin (final concentration 0.1 casein unit/ml or 45 nM) for 20 min at 37°C. From the activated scu-PA solution, 75 /tl was added to 175 u1 of 0.43 mM S-2444 in 50 mM Tris/HCl/38 mM NaCl/0.01 % Tween-80/aprotinin (20 kallikrein-inhibitory units/ml), pH 8.8. The increase in A405 was measured during incubation at 37°C by using a Titertek Multiskan instrument (Eflab Oy, Finland) . In this assay scu-PA was thus fully activated before measurement of tcu-PA.
Inactivation of scu-PA
The assay for inactivation ofscu-PA was performed by incubating 4.4 nM scu-PA with 0-16 nM thrombin in the absence or presence of rabbit TM, TM mutants CSGAG or chondroitin sulphate A in 20 mM Tris/HCl (pH 7.5)/100 mM NaCl/3 mM CaCl2/0.1 % BSA/0. 1 % Tween-80 for 45 min at 37 'C. Thrombin was preincubated with the components in the incubation buffer for 5 min at 37 'C, immediately before adding scu-PA. The reaction was stopped by adding hirudin (with a final concentration of 0.2 unit/ml or more, depending on the amount of thrombin present in the solution) and scu-PA activity was determined.
Chondroltinase ABC treatment Rabbit TM (81 nM, 500 1l) and low-and high-Mr rec-TM 720 nM, 200 ul) were incubated overnight at 37°C with and without chondroitinase ABC in 50 mM Tris/HCl (pH 8.0)/ 100 mM NaCl/30 ,M sodium acetate, in the presence of 2.5 mM 1 ,10-phenanthroline, 10 ,ug/ml pepstatin, and 20 /,g/ml leupeptin (Parkinson et al., 1990 ). The chondroitinase ABC concentration amounted to 250 munits/ml and was enhanced to 500 munits/ ml after 6 h.
Alkaline fl-elimination High-M, rec-TM (1.15 ,uM, 15 #l) was added to 135 ,1 of 0.1 M NaCl/0.56 M NaOH/0.1 % Tween-80 and incubated for 15 h at 4°C to release 0-linked saccharides from the protein . The solution was neutralized with HCI and tested in the inactivation assay of scu-PA. It is assumed that the CSGAG accounts for 10 % (w/w) of the high-Mr rec-TM .
RESULTS
To compare the accelerating effect of different TM preparations on the thrombin inactivation of scu-PA, various concentrations of thrombin were incubated with 4.4 nM scu-PA for 45 min at 37°C, in the absence or presence of excess rabbit TM (13.5 nM), human high-M, rec-TM (13.5 nM) or human low-Mr rec-TM (27 nM). The residual native scu-PA was activated by plasmin and quantified by using S-2444 ( Figure 1) ; 50 % of scu-PA was inactivated by 0.10 nM thrombin in complex with rabbit TM, by 0.11 nM thrombin in complex with high-M, rec-TM, by 1.9 nM thrombin in complex with low-Mr rec-TM and by 4.7 nM thrombin in the absence of TM. All three thrombin-TM complexes, as well as free thrombin, inactivated low-Mr scu-PA (7.3 nM) to the same extent as the intact scu-PA (Table 1) . This indicated that the epidermal-growth-factor domain and the kringle domain of scu-PA are not involved in the inactivation reaction.
With increasing concentrations of high-and low-M, rec-TM and a fixed thrombin concentration the acceleration of the scu-PA inactivation reached a maximum level (Figure 2) , at which all the thrombin was assumed to have formed a 1: 1 complex with rec-TM. The apparent Kd for this complex was determined as follows (De Munk et al., 1991) . The percentages of remaining scu-PA were converted into concentrations of thrombin-rec-TM complex, by reference to the standard curves prepared with various concentrations of thrombin in the presence of an excess of the corresponding rec-TM (Figure 1 ). The concentrations of free and bound rec-TM were then calculated and doublereciprocal plots (insets to Figures 2a and 2b) [Thrombin] (nM)
Effect of different types of TM on the inactivation of scu-PA by
The percentages of scu-PA remaining after incubation for 45 min at 37°C with various concentrations of thrombin in the absence (0) or in the presence of excess rabbit TM (13.5 nM) (*), high-MA rec-TM (13.5 nM) (A) or low-M, rec-TM (27 nM) (v) were quantified with S-2444 after activation with plasmin. After treatment with chondroitinase ABC, which destroys the CSGAG moiety, rabbit TM (13.5 nM), high-M, rec-TM (13.5 nM), and low-Mr rec-TM (27 nM) were incubated with various concentrations of thrombin and 4.4 nM scu-PA for 45 min at 37 'C. Remaining scu-PA was determined. Figure 3 shows that the activities of high-Mr rec-TM and rabbit TM were markedly decreased and fell almost to the activity of low-Mr rec-TM. By contrast, the activity of low-M, rec-TM was unaffected by chondroitinase ABC (Figure 3 droitin sulphate A (0-100 ,ug/ml), which is closely related to the CSGAG moiety on TM Nawa et al., 1990) or intact high-M, rec-TM (0-6.7 nM or 0-700 ng/ml, corresponding to about 0-70 ng/ml CSGAG) were incubated with 2 nM thrombin and 4.4 nM scu-PA for 45 min at 37°C . Remaining scu-PA was measured (Figure 4 ). Both chondroitin sulphate A and the free CSGAG from TM showed a significant and roughly equal acceleration of the scu-PA inactivation by [Thrombin] (nM) Figure 5 Reconstitution of low-Mr rec-TM with CSGAG from high-Mr rec-TM Scu-PA and thrombin were incubated alone (0), with CSGAG (0.14 ,ug/ml or 13.5 nM)
obtained by alkaline fl-elimination of high-Mr rec-TM (*) and in the presence of both low-Mr rec-TM (27 nM) and CSGAG (0.14 ,ug/ml or 13.5 nM) from high-Mr rec-TM (U). Remaining scu-PA was determined. Broken lines represent inactivation of scu-PA by thrombin in the presence of low-Mr rec-TM (27 nM) (v) and high-Mr rec-TM (13.5 nM) (A) (taken from Figure 1 ).
thrombin. However, high concentrations were needed, about 1000-fold higher than with intact high-Mr rec-TM.
Reconstitution experiments were performed by incubating scu-PA (4.4 nM) and thrombin for 45 min at 37°C in the presence of both low-Mr rec-TM (27 nM) and CSGAG (0.14 ,tg/ml or 13.5 nM), isolated from high-M, rec-TM. Figure   5 shows that the accelerating effects of the two compounds were additive, but restoration to the level of intact high-Mr rec-TM was not achieved. These results indicate that the polypeptide of rec-TM and the CSGAG must be covalently linked for expression of full activity DISCUSSION Recent studies have shown that the anticoagulant protein TM may also have an antifibrinolytic activity by accelerating the inactivation of scu-PA by thrombin (De Munk et al., 1991; Molinari et al., 1992 ). The present study shows that this property of TM strongly depends on the presence of an 0-linked CSGAG, as demonstrated with two glycoforms of human soluble rec-TM as well as with rabbit TM.
Scu-PA was 500% inactivated in 45 min with 4.7 nM free thrombin and only 0.10 or 0.1 1 nM thrombin respectively in the presence of excess rabbit TM or human high-Mr rec-TM, indicating that the two TM preparations had equal accelerating effects. In the presence of an excess human low-Mr rec-TM, lacking the 0-linked CSGAG (Parkinson et al., 1990 (Parkinson et al., , 1992 Koyama et al., 199 la) , 1.9 nM thrombin was needed to inactivate 50 % scu-PA, thus showing only a slight accelerating effect.
The conclusion that only the CSGAG is responsible for the difference in activity of high-Me and low-Mr rec-TM was supported by the experiments in which treatment of high-Mr rec-TM with chondroitinase ABC led to the level of activity of the low-Mr form. The free CSGAG component, obtained from highMr rec-TM by alkaline f-elimination, as well as chondroitin sulphate A also accelerated the inactivation of scu-PA by thrombin, in agreement with a recent paper of Molinari et al. (1992) . However, on a carbohydrate weight basis, 1000-fold more free CSGAG was required than intact high-Mr rec-TM to obtain the same effect. Reconstitution experiments showed that the addition of CSGAG to low-Mr rec-TM did not achieve the accelerating activity of high-M, rec-TM. This indicates that the CSGAG should be linked to the TM polypeptide chain for the expression of the full activity of TM.
The accelerating effects of both high-Mr and low-Mr rec-TM were dose-dependent and showed an apparent Kd for their complexes with human thrombin of 0.4 and 14 nM respectively, somewhat lower than the Kd values for bovine thrombin of 3 and 16 nM respectively (Parkinson et al., 1990) . It can be concluded that the CSGAG on TM plays a pivotal role in the acceleration of the inactivation of scu-PA by thrombin, both by providing a secondary binding site for thrombin (Bourin et al., 1988; Preissner et al., 1990 ), leading to a higher affinity for thrombin, and by increasing the activity of the TM-thrombin complex towards scu-PA.
The action of TM in the scu-PA inactivation reaction is probably based on induction of a conformational change in thrombin upon binding to the epidermal-growth-factor modules 5 and 6 of TM (Musci et al., 1988) . Additional conformational change in thrombin caused by binding to the secondary binding site on the CSGAG moiety (Bourin et al., 1988; Preissner et al., 1990 ) might occur. An additional explanation for the pivotal role of the CSGAG could be that the CSGAG provides a binding site for high-and low-Mr scu-PA, resulting in a cyclic ternary complex between TM, thrombin and scu-PA. The idea of direct binding between TM and scu-PA is supported by the finding that active-site-blocked or thrombin-derived tcu-PA can inhibit the TM acceleration of the inactivation of scu-PA (Molinari et al., 1992) . On the other hand, in the inactivation of thrombin by antithrombin III, which is accelerated by TM, the CSGAG moiety is also essential (Preissner et al., 1990; Koyama et al., 199 la) , but binding of antithrombin III to TM could not be detected (Preissner et al., 1990) .
If TM binds scu-PA directly, the model used for the estimation of the dissociation constants of the TM-thrombin complex would be inappropriate. However, as the Kd values obtained with rabbit TM (De Munk et al., 1991) and with high-M, rec-TM ( Figure 2a) were very close to 0.5 nM, a value obtained in the literature by independent methods (Owen and Esmon, 1981; Haley et al., 1989) , the putative binding between TM and scu-PA is probably weak with regard to the strong binding between TM and thrombin and does not significantly affect the estimation of the Kd of the latter interaction.
In addition to the elucidation of some structure-function relationships in TM, this study may have interesting physiological implications. As discussed previously (Koyama et al., 199 la; Parkinson et al., 1992) , glycosylation of TM in vivo may vary in a species-, tissue-or organ-specific manner. By modulating the CSGAG on TM, cells could regulate their scu-PA-inactivating potential and thereby u-PA activity-dependent processes, such as fibrinolysis as well as cell migration, tissue destruction and remodelling (De Munk et al., 1991) . Finally, potential antifibrinolytic effects of TM molecules should be considered when they are tested for anti-thrombolytic therapy (Nawa et al., 1992) .
